Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 61 of 633 for:    test AND point-of-care

The Evaluation of Point of Care Testing for Determining Hemoglobin Levels in Geriatric Intensive Care Patients (hb levels)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03509987
Recruitment Status : Completed
First Posted : April 27, 2018
Last Update Posted : May 1, 2018
Sponsor:
Information provided by (Responsible Party):
MEHTAP HONCA, MD, Kecioren Education and Training Hospital

Brief Summary:
The aim of the present study was to compare hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.Forty geriatric patients requiring intensive care treatment were included in the study. Arterial blood sample was analyzed using HemaCue (HbHemaCueArterial), blood gas analyzer (Techno Medica, Gastat1800 series) (HbBGA) and an automated hematology analyzer (Cell Dyne 3700 System, Abbot Laboratories)(HbLab) as a reference method. Capillary blood measurements were performed (HbHemaCueCapillary) by HemaCue at bedside.

Condition or disease Intervention/treatment Phase
Point-of-Care Systems Device: HemaCue Not Applicable

Detailed Description:
The aim of the present study was to compare hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.Forty geriatric patients requiring intensive care treatment were included in the study. Arterial blood sample was analyzed using HemaCue (HbHemaCueArterial), blood gas analyzer (Techno Medica, Gastat1800 series) (HbBGA) and an automated hematology analyzer (Cell Dyne 3700 System, Abbot Laboratories)(HbLab) as a reference method. Capillary blood measurements were performed (HbHemaCueCapillary) by HemaCue at bedside. Bland Altman Analysis was applied to the results .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Evaluation of Point of Care Testing for Determining Hemoglobin Levels in Geriatric Intensive Care Patients
Actual Study Start Date : March 1, 2018
Actual Primary Completion Date : April 1, 2018
Actual Study Completion Date : April 5, 2018

Arm Intervention/treatment
hb analysis with Hemacue
Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
Device: HemaCue
comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
Other Name: Blood gas analyser




Primary Outcome Measures :
  1. hemoglobin levels [ Time Frame: 1 months ]
    comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • geriatric patients requiring intensive care treatment

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03509987


Locations
Layout table for location information
Turkey
Mehtap Honca
Ankara, Kecioren, Turkey, 06010
Sponsors and Collaborators
Kecioren Education and Training Hospital
Investigators
Layout table for investigator information
Principal Investigator: MEHTAP HONCA, Ass. Prof Kecioren training and research Hospital , Department of Anesthesiology and Reanimation

Layout table for additonal information
Responsible Party: MEHTAP HONCA, MD, Director, Kecioren Education and Training Hospital
ClinicalTrials.gov Identifier: NCT03509987     History of Changes
Other Study ID Numbers: KeciorenTRH
First Posted: April 27, 2018    Key Record Dates
Last Update Posted: May 1, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: Yes